Canaccord Genuity Thinks Aphria Inc’s Stock is Going to Recover

By Carrie Williams

According to The Fly, in a report released yesterday, Matt Bottomley from Canaccord Genuity reiterated a Buy rating on Aphria Inc (APHAResearch Report). The company’s shares closed yesterday at $4.51, close to its 52-week low of $4.42.

According to, Bottomley is ranked #519 out of 5124 analysts.

Aphria Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.

See today’s analyst top recommended stocks >>

Based on Aphria Inc’s latest earnings release for the quarter ending August 31, the company reported a quarterly net profit of $16.33 million. In comparison, last year the company had a net profit of $5.14 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aphria, Inc. engages in the production and supply of medical cannabis. Its products include cannabis capsules, oral solutions, concentrate syringes and tetrahydrocannabinol and cannabidiol vaporizers. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.